Literature DB >> 22088969

Ventilation/perfusion lung scan in pulmonary veno-occlusive disease.

Andrei Seferian1, Badia Helal, Xavier Jaïs, Barbara Girerd, Laura C Price, Sven Günther, Laurent Savale, Peter Dorfmüller, Florence Parent, Olivier Sitbon, Marc Humbert, Gérald Simonneau, David Montani.   

Abstract

Pulmonary veno-occlusive disease (PVOD), a rare form of pulmonary arterial hypertension (PAH), requires histological proof for definitive diagnosis; however, lung biopsy is not recommended in PAH. Recent conjoint European Respiratory Society/European Society of Cardiology guidelines suggest that nonmatched perfusion defects on ventilation/perfusion (V'/Q') lung scanning in PAH patients may suggest PVOD. The aim of our study was to evaluate V'/Q' lung scans in a large cohort of PVOD and idiopathic or heritable PAH patients. V'/Q' lung scans from 70 patients with idiopathic or heritable PAH and 56 patients with confirmed or highly probable PVOD were reviewed in a double-blind manner. The vast majority of V'/Q' lung scans were normal or without significant abnormalities in both groups. No differences in ventilation or perfusion lung scans were observed between PAH and PVOD patients (all p>0.05). Furthermore, no differences were observed between confirmed (n=31) or highly probable PVOD (n=25). Nonmatched perfusion defects were found in seven (10%) idiopathic PAH patients and four (7.1%) PVOD patients (p>0.05). Nonmatched perfusion defects were rarely seen in a large cohort of idiopathic or heritable PAH and PVOD patients. Future recommendations should be amended according to these results suggesting that V'/Q' lung scanning is not useful in discriminating PVOD from idiopathic PAH.

Entities:  

Mesh:

Year:  2011        PMID: 22088969     DOI: 10.1183/09031936.00097911

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  6 in total

1.  Pulmonary hypertension nosography: are all patients classifiable?

Authors:  Elena Torricelli; Mariaelena Occhipinti; Federico Lavorini; Chiara Cresci; Chiara Arcangeli; Edoardo Cavigli; Francesca Bigazzi; Massimo Pistolesi
Journal:  Intern Emerg Med       Date:  2017-06-30       Impact factor: 3.397

Review 2.  Chronic Thromboembolic Pulmonary Hypertension.

Authors:  Krittika Teerapuncharoen; Remzi Bag
Journal:  Lung       Date:  2022-05-29       Impact factor: 2.584

3.  2014 Guidelines of Taiwan Society of Cardiology (TSOC) for the Management of Pulmonary Arterial Hypertension.

Authors:  Chih-Hsin Hsu; Wan-Jing Ho; Wei-Chun Huang; Yu-Wei Chiu; Tsu-Shiu Hsu; Ping-Hung Kuo; Hsao-Hsun Hsu; Jia-Kan Chang; Chin-Chang Cheng; Chao-Lun Lai; Kae-Woei Liang; Shoa-Lin Lin; Hsao-Hsun Sung; Wei-Chuan Tsai; Ken-Pen Weng; Kai-Sheng Hsieh; Wei-Hsian Yin; Shing-Jong Lin; Kuo-Yang Wang
Journal:  Acta Cardiol Sin       Date:  2014-09       Impact factor: 2.672

4.  The role of nuclear imaging in pulmonary hypertension.

Authors:  H Ohira; R S Beanlands; R A Davies; L Mielniczuk
Journal:  J Nucl Cardiol       Date:  2014-08-27       Impact factor: 5.952

5.  Pulmonary Veno-Occlusive Disease: A Rare Cause of Pulmonary Hypertension.

Authors:  Said Hajouli; Muhamad Alhaj Moustafa; Jessica S Wang Memoli
Journal:  J Investig Med High Impact Case Rep       Date:  2019 Jan-Dec

6.  Association Between Anticoagulation Outcomes and Venous Thromboembolism History in Chronic Thromboembolic Pulmonary Hypertension.

Authors:  Yong-Jian Zhu; Yu-Ping Zhou; Yun-Peng Wei; Xi-Qi Xu; Xin-Xin Yan; Chao Liu; Xi-Jie Zhu; Zi-Yi Liu; Kai Sun; Lu Hua; Xin Jiang; Zhi-Cheng Jing
Journal:  Front Cardiovasc Med       Date:  2021-05-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.